Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 29, 2005British Journal of HaematologyOpen Access

Protecting against anthracycline‐induced myocardial damage: a review of the most promising strategies

View Full Paper
Ask AI
Bookmark
Share

Why the study?

What are the most promising strategies to limit or prevent anthracycline-induced cardiotoxicity in children and adults?

Population

Children and adults receiving anthracycline treatment for cancer

Design

Review

Authors

KWKarlijn A. WoutersZaans Medisch CentrumLKLeontien C.M. KremerHeart Failure / CardiomyopathyTMTracie L. MillerUniversity of Missouri–Kansas City

Discussion

Loading...

Member takes

Implication

May guide anthracycline cardiotoxicity prevention in practice; leaves open optimal strategies pending prospective trials.

Key Points

  • Evaluate the biological mechanisms of anthracycline-induced cardiotoxicity and summarize promising clinical strategies to prevent or mitigate myocardial damage.
  • Reviewed mechanistic pathways responsible for anthracycline-mediated cardiac injury in pediatric and adult cancer populations.
  • Synthesized evidence on preventive interventions aimed at reducing cardiotoxicity and halting the progression of existing cardiomyopathy.
  • Identified cardiotoxicity as a major dose-limiting adverse effect of anthracyclines that elevates long-term risks of congestive heart failure and heart transplantation.
  • Highlighted targeted cardioprotective strategies that may enable higher therapeutic chemotherapy dosing while improving long-term quality of life and survival.

Structured PICO

What are the most promising strategies to limit or prevent anthracycline-induced cardiotoxicity in children and adults?

P
Population
Children and adults receiving anthracycline treatment for cancer
I
Intervention
Strategies to limit or prevent anthracycline-induced cardiotoxicity
O
Outcome
Anthracycline-induced cardiotoxicity and myocardial damage

This review summarizes current strategies to prevent or limit anthracycline-induced cardiotoxicity, which could improve cancer survival and quality of life.

Cite This Study

Wouters et al. (2005) studied this question.

synapsesocial.com/papers/6a1bc4a7b33628da419cd3cdhttps://doi.org/10.1111/j.1365-2141.2005.05759.x

Topics

Heart failureHFrEF treatmentCardio-oncology
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Reduction of O2 by iron-adriamycin.1984 · 77 citations
  2. 2Epirubicin cardiotoxicity: an analysis of 469 patients with metastatic breast cancer.1998 · 289 citations
  3. 3ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.1992 · 324 citations
  4. 4Phosphodiesterase-5 Inhibition With Sildenafil Attenuates Cardiomyocyte Apoptosis and Left Ventricular Dysfunction in a Chronic Model of Doxorubicin Cardiotoxicity2005 · 355 citations
  5. 5Growth Hormone Treatment in Dilated Cardiomyopathy2001 · 62 citations